CERETEC Drug Patent Profile

When do Ceretec patents expire, and what generic alternatives are available?

Ceretec is a drug marketed by Ge Healthcare and is included in one NDA.

The generic ingredient in CERETEC is technetium tc-99m exametazime kit. There are four drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the technetium tc-99m exametazime kit profile page.

Summary for CERETEC

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for CERETEC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ge Healthcare	CERETEC	technetium tc-99m exametazime kit	INJECTABLE;INJECTION	019829-001	Dec 30, 1988		RX	Yes	Yes

International Patents for CERETEC

See the table below for patents covering CERETEC around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	123504
Japan	S61225159	COMPLEX OF TECHNETIUM 99M WITH PROPYLENEAMINE OXIME
United Kingdom	8509368
Japan	H0211593
Japan	H06184078	COMPLEX OF TECHNETIUM 99 M WITH PROPYLENEAMINE OXIME
Australia	5460986

Supplementary Protection Certificates for CERETEC

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1178838	300736	Netherlands		PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119

Last updated: February 10, 2026

What is CERETEC and Its Market Position?

CERETEC is a radiopharmaceutical product with the active ingredient technetium-99m (Tc-99m) methylene diphosphonate (MDP). It is used primarily for bone imaging to detect bone metastases, fractures, infections, and other abnormalities. Approved for diagnostic imaging, CERETEC is marketed globally, with significant adoption in nuclear medicine clinics.

Market penetration hinges on nuclear medicine infrastructure, clinical demand for bone imaging, and the regulatory environment. Its primary competitors include other Tc-99m-based bone tracers such as Xe-99m, and newer, PET-based agents. The global nuclear medicine market was valued at approximately $4.3 billion in 2022, with bone imaging accounting for roughly 20% of the segment [1].

What Are the Key Investment Drivers for CERETEC?

Market Demand

Bone imaging remains a standard diagnostic tool, especially in oncology to quantify bone metastases. The estimated global incidence of cancers prone to bone metastases (breast, prostate, lung) supports sustained demand. Estimated annual procedures number over 10 million worldwide [2].

Production and Supply Chain Economics

CERETEC’s supply depends on the availability of technetium-99m, derived from molybdenum-99 (Mo-99) generators. The supply chain has experienced disruptions, but recent investments in new reactors and regional distribution centers aim to stabilize supply. Cost efficiency arises from the widespread clinical use and relatively easy shipping of Tc-99m radiopharmaceuticals.

Regulatory Environment and Approvals

CERETEC retains approval in several major markets, including the U.S., Europe, and Asia. Expedited pathways and approval extensions in emerging markets can bolster revenue. Unlike PET tracers, Tc-99m-based agents face fewer regulatory hurdles, supporting broader accessibility.

Competitive Landscape and Innovation

While GPT-based and PET bone imaging agents, such as fluoride PET, offer higher resolution, their higher costs limit widespread adoption. CERETEC’s low-cost, established infrastructure position it as a cost-effective diagnostic option, supporting sustained usage.

What Are Potential Risks and Challenges?

Supply Chain Vulnerabilities

Dependence on Mo-99 generator availability exposes CERETEC to supply disruptions. Global efforts for reactor upgrades and alternative production methods aim to mitigate this but remain a concern.

Competition from PET Agents

Advances in PET technology, offering higher sensitivity and resolution, threaten to replace Tc-99m agents in some markets. Transitioning to PET-based diagnostics requires infrastructure investment, limiting immediate impact on CERETEC’s core market.

Regulatory and Market Access

Changing regulations or toughening of approval standards could impact market access. The evolving healthcare policies in emerging economies could alter reimbursement rates and clinical adoption patterns.

Market Saturation

High penetration in established markets might slow revenue growth. Future demand depends on aging populations and increasing cancer incidence.

What Is the R&D and Pipeline Outlook?

CERETEC itself has limited R&D activity as a mature product. However, companies involved in its production and distribution are exploring longer-lived isotopes, alternative delivery systems, and combined imaging modalities. Innovation in radiopharmaceutical logistics and automation can enhance profitability for existing products.

What Are the Financial Fundamentals?

Specific financial data for CERETEC are proprietary; however, industry averages provide benchmarks:

• Revenue from nuclear medicine radiopharmaceuticals is expected to grow at approximately 4-5% annually through 2027 [3].

• Profit margins for radiopharmaceuticals generally hover around 20-30%, driven by manufacturing efficiencies and high clinical demand.

• R&D expenditure typically accounts for 10-15% of revenue within the biotech sector, with mature products like CERETEC requiring minimal ongoing R&D.

Investment in supply chain capacity, especially Mo-99 production, correlates positively with sales stability. Licensing and distribution agreements influence revenue sharing, with some companies holding exclusive rights in key territories.

What Are Strategic Considerations?

Investors should monitor regulatory developments, supply chain robustness, and competitive shifts toward PET imaging. Companies that diversify isotope production or develop next-generation agents could alter competitive dynamics. Licensing agreements and collaborations shape market access and profitability.

Conclusion

CERETEC is a validated, cost-effective bone imaging agent with stable demand driven by cancer diagnostics and fracture assessments. Its reliance on Mo-99 supply chains presents risks but also opportunities for strategic partnerships and infrastructure investments. Competition from advanced imaging modalities poses a medium-term challenge, but current adoption levels and cost advantages support its ongoing relevance.

Key Takeaways

• CERETEC is a widely used Tc-99m-based bone imaging agent with global market presence.
• Market demand remains steady, supported by high-volume cancer diagnostics.
• Supply chain risks center on Mo-99 reactor dependence; ongoing diversification efforts seek mitigation.
• PET imaging agents pose competitive threats but face adoption barriers related to cost and infrastructure.
• Financial growth depends on market expansion, regulatory landscape, and supply chain stability.

FAQ

Q1: How does CERETEC compare to PET-based bone imaging agents?
A: CERETEC is generally cheaper and benefits from established infrastructure. PET agents offer higher resolution but involve higher costs and newer technology.

Q2: What factors influence production costs of CERETEC?
A: Costs are driven by Mo-99 generator prices, reactor availability, isotope separation, and distribution logistics.

Q3: Which markets are most attractive for CERETEC investment?
A: North America and Europe, due to high clinical volume and mature healthcare infrastructure, present stable opportunities. Emerging markets provide growth due to increasing diagnostic access.

Q4: What are the regulatory challenges facing CERETEC?
A: Variations in approval processes and reimbursement policies across regions influence market access. The evolving nuclear medicine regulations aim to ensure safety but can delay product approval or reimbursement.

Q5: How will technological advancements impact CERETEC’s future?
A: Innovations favoring PET, such as higher sensitivity and diagnostic accuracy, could reduce demand for Tc-99m agents like CERETEC over time, unless cost advantages sustain its market share.

---

Citations

[1] MarketsandMarkets, "Nuclear Medicine Market," March 2022.
[2] World Health Organization, "Cancer Fact Sheets," 2021.
[3] Deloitte, "Industry Outlook: Radiopharmaceuticals," 2022.